BioAlliance Pharma extends its Loramyc(TM) License to China with NovaMed, Inc.
PARIS--(MARKET WIRE)--Jun 23, 2008 -- BioAlliance Pharma extends its Loramyc(TM) License to China through an agreement with NovaMed Pharmaceuticals
Paris, June 23th, 2008 - BioAlliance Pharma SA (Euronext Paris -BIO), the specialty pharmaceutical company focused on the treatment of opportunistic infections in cancer and HIV, today announced that it has entered into an exclusive licensing agreement under which NovaMed Pharmaceuticals will receive commercialization rights in China for Loramyc(TM). Loramyc(TM) (miconazole Lauriad®), BioAlliance Pharma's innovative, muco-adhesive antifungal therapy, is already approved in Europe and completed a Phase III clinical trial in the United States in immunocompromised patients.
Paris, June 23th, 2008 - BioAlliance Pharma SA (Euronext Paris -BIO), the specialty pharmaceutical company focused on the treatment of opportunistic infections in cancer and HIV, today announced that it has entered into an exclusive licensing agreement under which NovaMed Pharmaceuticals will receive commercialization rights in China for Loramyc(TM). Loramyc(TM) (miconazole Lauriad®), BioAlliance Pharma's innovative, muco-adhesive antifungal therapy, is already approved in Europe and completed a Phase III clinical trial in the United States in immunocompromised patients.